Alchemab Therapeutics

About:

Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.

Twitter/X: AlchemabTx

Top Investors: RA Capital Management, SV Health Investors, Dementia Discovery Fund, DCVC, Michael J. Fox Foundation

Description:

Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. The company is building their transformative engine to identify drug targets and develop a pipeline of antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. Alchemab Therapeutics was established in 2019 by Uri Laserson and Jane Osbourn in London, England.

Total Funding Amount:

$85.6M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2019-01-01

Contact Email:

info(AT)alchemab.com

Founders:

Alex Leech, Ben Larman, Jane Osbourn, Rachael Bashford-Rogers, Uri Laserson

Number of Employees:

11-50

Last Funding Date:

2024-06-06

IPO Status:

Private

Industries: